Posts tagged Canaccord Genuity
Titan Pharma in talks with Braeburn about future of Probuphine partnership

Titan Pharmaceuticals (NASDAQ:TTNP) is in discussions with Braeburn Pharmaceuticals about their partnership for the development and commercialization of Probuphine, the first six-month maintenance treatment of opioid dependence. 

Read More
Canaccord ups OraSure price target to $18

Canaccord Genuity raised its price target for OraSure Technologies (NASDAQ:OSUR) to $18 from $15 after the company entered a four-year, up to $20-million agreement with the Bill & Melinda Gates Foundation, which will effectively subsidize the cost of the HIV self test.

Read More
Canaccord ups STAAR Surgical price target to $9

Canaccord Genuity raised its price target for STAAR Surgical (NASDAQ:STAA) to $9 from $7, but maintained its “hold” rating after the company reported fourth quarter results. The stock closed at $10.18 on March 2.

Read More
3DS raises $3.9-million in oversubscribed private placement

3D Signatures (TSX-V:DXD) issued 5,187,618 units under a brokered private placement at a price of 75 cents a unit for gross proceeds of about $3.9-million, including a partial exercise of an over-allotment option.

Read More
Canaccord and BTIG start iRhythm at buy

BTIG initiated coverage of iRhythm Technologies (NASDAQ:IRTC) with a “buy” rating and a $28 price target. The stock closed at $24.23 on Friday.

iRhythm is a digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distil data from millions of heartbeats into clinically actionable information.

Read More
Canaccord ups AtriCure price target to $23

Canaccord Genuity raised its price target for AtriCure (NASDAQ:ATRC) to $23 from $21 after the company reported third quarter results. The stock is trading at $17.74, up $2.54, at midday on Friday.

The third quarter represented “sentiment-changing results for an under-appreciated, under-valued, high margin med-tech growth story,” writes analyst Jason Mills. “Bottom line: buy this stock,” he added.

Read More
Canaccord ups CryoLife price target to $23.50

Canaccord Genuity raised its price target for CryoLife (NYSE:CRY) to $23.50 from $17.50 after the company reported third quarter results. The stock is changing hands at $17.10 on Thursday afternoon.

Analyst Jason Mills writes that CryoLife posted a significant earnings beat on solid sales growth, higher gross margins and operating expense leverage flowing through to the bottom line.

Read More
Canaccord upgrades Endologix to buy

Canaccord Genuity has upgraded Endologix (NASDAQ:ELGX) to “buy” from “hold” and raised its price target to $15.50 from $11.25. The stock closed at $12.68 on Friday.

The company is developing Nellix as an endovascular aneurysm sealing (EVAS) system designed for the treatment of infrarenal abdominal aortic aneurysm (AAA) and is the only technology whose operating principle is centered on sealing the aneurysm sac.

Read More
Canaccord ups GenMark price target to $10.50

Canaccord Genuity has hiked its price target for GenMark Diagnostics (NASDAQ:GNMK) to $10.50 from $8. The stock closed at $9.27 on Wednesday.

After the close yesterday, GNMK announced a major milestone, achieving CE Mark for both its ePlex instrument and ePlex Respiratory Pathogen Panel, which was three weeks ahead of its recent timeline by the end of June.

Read More
Canaccord ups Spectranetics price target to $23.50

Canaccord Genuity has raised its price target on Spectranetics (NASDAQ:SPNC) to $23.50 from $20. The stock closed at $16.68 on Thursday.

“Our bullish conviction heading into the Q1 print was validated by the strong quarterly performance that reflected a continuation of the positive trends from the second half of 2015,” writes analyst Jason Mills.

Read More
Canaccord starts CryoLife at buy

Canaccord Genuity has launched coverage of CryoLife (NYSE:CRY) with a “buy” rating and $14 yearend price target. The stock closed at $11 on Tuesday.

“We recommend small-cap GARP (growth at a reasonable price) investors build positions in CryoLife, which is actively building a cardiac surgery-focused company through targeted acquisitions that augment its strong, existing core franchise and strategic divestitures,” writes analyst Jason Mills.

Read More